RayzeBio
Actinium-based radiopharmaceutical therapies for cancer treatment
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Founded
- 2020
- Latest Form D
- $168M, Sep 2022
- Total capital
- $396M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $396M
- 4 Form D · last Sep 2022
- 49 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 36 pending · first 2022
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$168M
- Private capital raisedForm D · SEC · 3rd filing$109M
- Private capital raisedForm D · SEC · 2nd filing$105M
- Private capital raisedForm D · SEC · 1st filing$15M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Aaron KantoffDirectorNamed in SEC Form D filings
- Aaron RoystonDirectorNamed in SEC Form D filings
- Alex RosenDirectorNamed in SEC Form D filings
- Angie YouDirectorNamed in SEC Form D filings
- Arvind KushExecutive OfficerNamed in SEC Form D filings
- Aubrey HaddachExecutive OfficerNamed in SEC Form D filings
Show all 13 people
- Bong KohDirectorNamed in SEC Form D filings
- Deborah CharychExecutive OfficerNamed in SEC Form D filings
- Jerel DavisDirectorNamed in SEC Form D filings
- Ken SongExecutive Officer, DirectorNamed in SEC Form D filings
- Maha KatabiDirectorNamed in SEC Form D filings
- Mary TagliaferriDirectorNamed in SEC Form D filings
- Yi LarsonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 40- PendingRadiopharmaceutical Compositions Targeting Glypican-3 and Uses ThereofUSPTOApplication 19395559
- PendingRadiopharmaceutical Compositions Targeting Alpha V Beta 6 Integrin Receptor and Method of Uses ThereofUSPTOApplication 19426693
- PendingCompounds Targeting Carbonic Anhydrase IX and Uses ThereofUSPTOApplication 19379951
Show all 40 patent records
- Radiopharmaceutical Compositions Targeting Glypican-3 and Uses ThereofAug 20, 2026 · Application 19395559Pending
- Radiopharmaceutical Compositions Targeting Alpha V Beta 6 Integrin Receptor and Method of Uses ThereofAug 6, 2026 · Application 19426693Pending
- Compounds Targeting Carbonic Anhydrase IX and Uses ThereofMay 7, 2026 · Application 19379951Pending
- Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses ThereofJul 10, 2025 · Application 18989485Pending
- Stabilized Compositions Of Radionuclides And Uses ThereofFeb 27, 2025 · Application 18649569Pending
- Conjugates Comprising Covalent Binders For Targeting Intracellular ProteinsFeb 20, 2025 · Application 18431656Pending
- Conjugates Comprising Covalent Binders For Targeting Intracellular ProteinsOct 17, 2024 · Application 18434621Pending
- Conjugates Comprising Covalent Binders For Targeting Intracellular Kras G12C ProteinsAug 1, 2024 · Application 18431646Pending
- Stabilized Compositions Of Radionuclides And Uses ThereofApr 18, 2024 · Application 18511854Pending
- Stabilized Compositions Of Radionuclides And Uses ThereofNov 21, 2023 · US 11,819,556Granted
- Stabilized Compositions Of Radionuclides And Uses ThereofJul 25, 2023 · US 11,707,540Granted
- Radiopharmaceutical Conjugate Compositions And Uses ThereofMay 25, 2023 · Application 17989479Pending
- Stabilized Compositions Of Radionuclides And Uses ThereofJan 3, 2023 · US 11,541,134Granted
- Stabilized Compositions Of Radionuclides And Uses ThereofNov 15, 2022 · US 11,497,822Granted
- Radiopharmaceuticals Targeting Somatostatin Receptor 2 And Uses ThereofApplication 63614474Pending
- Radiopharmaceutical Compositions Targeting Somatostatin Receptors And Uses ThereofApplication 63614482Pending
- Radiopharmaceutical Compositions Targeting Ephrin Type-a Receptor 2 And Uses ThereofApplication PCTUS2023075451Pending
- Radiopharmaceutical Compositions Targeting GLYPICAN-3 And Uses ThereofApplication 63506721Pending
- Methods for Treating SSTR Positive CancerApplication 19486211Pending
- Methods For Treating Sstr Positive CancerApplication PCTUS2023024352Pending
- Methods For Treating Sstr Positive CancerApplication 63504696Pending
- Radiopharmaceutical Compositions Targeting Carbonic Anhydrase Ix And Uses ThereofApplication 63499666Pending
- Radiopharmaceutical Compositions Targeting Ephrin Type-a Receptor 2 And Uses ThereofApplication 63411307Pending
- Radiopharmaceutical Compositions Targeting Ephrin Type-a Receptor 2 And Uses ThereofApplication 63411380Pending
- Conjugates Comprising Covalent Binders For Targeting Intracellular ProteinsApplication PCTUS2022039601Pending
- Conjugates Comprising Covalent Binders For Targeting Intracellular Kras G12C ProteinsApplication PCTUS2022039589Pending
- Stabilized Compositions Of Radionuclides And Uses ThereofApplication 63329306Pending
- Compositions And Methods For Modifying Kras G12C With Covalent RadionuclidesApplication 63299698Pending
- Radiopharmaceutical Conjugates Targeting Guanylyl Cyclase C, And Compositions And Uses ThereofApplication PCTUS2021061252Pending
- Radiopharmaceutical Conjugate Compositions And Uses ThereofApplication PCTUS2021061186Pending
- Conjugates Comprising Covalent Binders For Targeting Intracellular Kras G12C ProteinsApplication 63230432Pending
- Conjugates Comprising Covalent Binders For Targeting Intracellular ProteinsApplication 63230439Pending
- Stabilized Compositions Of Radionuclides And Uses ThereofApplication 63228535Pending
- Radiopharmaceutical Conjugates Targeting Guanylyl Cyclase C, And Compositions And Uses ThereofApplication 63119557Pending
- Radiopharmaceutical Conjugate Compositions And Uses ThereofApplication 63119555Pending
- Radiopharmaceutical Compositions Targeting Alpha V Beta 6 Integrin Receptor And Method Of Uses ThereofApplication PCTUS2025060566Pending
- Radiopharmaceutical Compositions Targeting Somatostatin Receptors and Uses ThereofApplication 19597146Pending
- Radiopharmaceutical Compositions Targeting GLYPICAN-3 And Uses ThereofApplication PCTUS2025058892Pending
- Compounds Targeting Carbonic Anhydrase Ix And Uses ThereofApplication PCTUS2025054091Pending
- Radiopharmaceutical Compositions Targeting Carbonic Anhydrase IX and Uses ThereofApplication 19478383Pending
Related companies, and why
- Zura Bio LtdSimilar federal contract value in Biotech · null in contracts
- Galecto, Inc.Similar federal contract value in Biotech · null in contracts
- Allogene TherapeuticsSimilar federal contract value in Biotech · null in contracts
- ImvaxSimilar federal contract value in Biotech · null in contracts
- Zenas BioPharmaSimilar federal contract value in Biotech · null in contracts
- ProEncia Biotechnology Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .